Bone metastases frequently occur in the advanced stages of breast cancer. At this stage, the disease is deemed incurable. To date, the mechanisms of breast cancer-related metastasis to bone are poorly understood. This may be attributed to the lack of appropriate animal models to investigate the complex cancer cell-bone interactions. In this study, two established tissue-engineered bone constructs (TEBCs) were applied to a breast cancerrelated metastasis model. A cylindrical medical-grade polycaprolactone-tricalcium phosphate scaffold produced by fused deposition modelling (scaffold 1) was compared with a tubular calcium phosphate-coated polycaprolactone scaffold fabricated by solution electrospinning (scaffold 2) for their potential to generate ectopic humanised bone in NOD/SCID mice. While the scaffold 1 was found not suitable to generate a sufficient amount of ectopic bone tissue due to poor ectopic integration, the scaffold 2 showed excellent integration into the host tissue, which did lead to bone formation. To mimic breast cancer cell colonisation to the bone, MDA-MB-231, SUM1315 and MDA-MB-231BO breast cancer cells were cultured in polyethylene glycol-based hydrogels and implanted adjacent to the TEBCs. Histological analysis indicated that the breast cancer cells induced an osteoclastic reaction in the TEBCs, demonstrating analogies to breast cancer-related bone metastasis seen in patients.
Introduction
Breast cancer is the most common malignancy in women according to the WHO, and over half a million women died from this disease in 2011 (DeSantis et al. 2011) . Survival rates vary from 80% for example in North America, Sweden and Japan to approximately 40-60% in middle-income and low-income countries (Coleman M. P. et al. 2008) . This wide range might be due to inadequate treatment, lack of early detection and poor diagnostic tools, thus women are diagnosed with the advanced stage of the disease (Coleman M. P. et al. 2008) .
Despite the availability of well-established treatment modalities, including surgery, chemo-, radiation-and anti-hormonal therapy, and therefore high survival rates in high-income countries, at least 10-15% of breast cancer patients develop metastases after years of disease-free survival (Coleman R. E. and Rubens 1987) (Psaila et al. 2006) . Breast cancerrelated metastases mainly affect the skeleton followed by the liver, lung and brain (Coleman R. E. and Rubens 1987) (Kozlow and Guise 2005) . The skeleton represents the major tissue This article is protected by copyright. All rights reserved.
for breast cancer metastases, about 83% of women with advanced disease suffer from this debilitating stage.
Bone metastases are classified according to their radiographic appearance as osteolytic or osteoblastic (Thibaudeau et al. 2014a) . Both types of bone lesions are caused by an imbalance between bone resorption through activated osteoclasts and new bone formation through osteoblasts. Osteolytic lesions show a deficient new bone formation, while osteoblastic lesions have a disorganised new bone formation with impaired bone resorption (Thibaudeau et al. 2014a) . Osteolytic lesions are predominant in breast cancer-related bone metastasis (Yu et al. 2012) . Symptoms associated with bone metastases are due to extensive bone loss and tumour expansion, and include severe bone pain, pathological fractures, spinal cord compression and hypercalcaemia (Kozlow and Guise 2005) (Yu et al. 2012) . Current treatment options for bone metastasis are seldom curative and focus on pain management (Thibaudeau et al. 2014a) . The frequency of pathological fractures can be decreased through palliative treatment with anti-resorptive drugs like bisphosphonates and the RANKL antibody denosumab (Thibaudeau et al. 2014a) . These treatments improve the quality of life, but fail to prolong patient survival (Daniele et al. 2011) (Brown et al. 2004 ).
The restricted treatment options are due to the fact that underlying mechanisms of breast cancer-related bone metastasis are not fully understood which in turn results from the lack of appropriate in vitro and in vivo models to study this disease. Current in vivo approaches investigate the homing of human breast cancer cells to the murine skeleton in immunecompromised hosts. These models present two disadvantages. Firstly, injection of cancer cells into the murine circulatory system via tail vein or left ventricle bypasses the first steps of the metastatic cascade (Kang et al. 2003) . Secondly, interspecies phenomena are examined as human breast cancer cells interact with the murine bone. Yonou et al. (Yonou et al. 2001) were the first to use adult human bone fragments as metastatic target for osteotropic cancer cells as opposed to the murine skeleton. However, the route of cancer cell injection remained the same (Lau et al. 2013) (Khanna and Hunter 2005) . Other models utilised cell carrier systems, such as Matrigel or other hydrogels, to induce a human breast tumour at its orthotopic site, the murine mammary fat pad, to recapitulate the metastatic cascade but failed to generate a bone marrow compartment (Kuperwasser et al. 2005) . Since then, only a few models used human bone fragments in conjunction with orthotopic breast tumours (Xia et al. 2012) . However, these models are linked with partial necrosis of the bone fragments due to delayed neo-vascularisation, high variability and donor dependency, resulting in poor reproducibility (Moreau et al. 2007) . A strategy to overcome these complications has been the introduction of a bone tissue engineering (TE) approach (Thibaudeau et al. 2014a ) (Thibaudeau et al. 2014b ) (Schuster et al. 2006) (Bersani et al. 2014) (Seib et al. 2015) .
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Scaffolds for the purpose of bone TE need to have a high elastic modulus and an interconnected macro-pore structure of 300-500 μm to enhance diffusion rates to and from the scaffold centre and to allow the transport of nutrients and by-products (Hutmacher 2000) .
Medical-grade polycaprolactone-tricalcium phosphate (mPCL-TCP) scaffolds produced by fused deposition modelling meet the aforementioned requirements (Hutmacher 2000) .
Composite scaffolds represent a combination of bioactive ceramics, such as calcium phosphate (CaP), with a polymer, such as mPCL, to combine the favourable mechanical properties of the biodegradable polymer with the osteoconductive characteristics of the ceramic component (Zhou et al. 2007 ). Previously, mPCL-TCP scaffolds have been used in rat and rabbit skull defect models as well as in a spinal fusion model with promising outcomes (Hutmacher and Cool 2007) . To further improve the osteoinductivity of these bone TE approaches, scaffolds have been used in conjunction with osteogenic progenitor cells and growth factors like bone morphogenetic proteins (BMPs) (Arthur et al. 2009 ) (Biggs et al. 2009 ) (Santos et al. 2009 ).
This study shows the attempt to translate an orthotopic bone TE approach to an ectopic humanised NOD/SCID model. This approach has already been successfully used by our group to mimic the invasion of the humanised bone by breast cancer cells upon intra-cardiac injection (Thibaudeau et al. 2014a ) (Thibaudeau et al. 2014b) . Herein, the development of a model of direct bone colonisation, by implanting cell-loaded hydrogels adjacent to the tissueengineered bone constructs (TEBCs), opposed to the experimental or spontaneous metastasis approach, is described. Therefore, two TEBCs with different architectures and manufacturing techniques were compared.
Materials and Methods

Isolation of human osteoblasts
Primary human osteoblasts (hOBs) were isolated from explants obtained from patients undergoing knee replacement surgery as approved by the Queensland University of Technology and Prince Charles Hospital ethics committees (approval number 0600000232).
Non-sclerotic, trabecular bone from the tibial plateau was collected, minced, washed and transferred into tissue culture flasks containing α-Minimal Essential Medium (α-MEM), 10% FBS, penicillin (100 IU/ml) and streptomycin (0.1 mg/ml). (0.01 mg/ml) and cholera toxin (100 ng/ml). SUM1315 cells were cultured in DMEM/F-12, EGF (10 ng/ml) and insulin (5 μg/ml). MDA-MB-231 and MDA-MB-231-BO cells were maintained in DMEM. Each medium contained 10% FBS, penicillin (100 IU/ml) and streptomycin (0.1 mg/ml).
2.3. Scaffold fabrication using fused deposition modelling (scaffold 1)
Composite mPCL-TCP scaffolds were produced by fused deposition modelling (Osteopore International, Singapore). Composite scaffold sheets (mPCL:TCP, 80:20) measuring 100×100×4 mm, with a lay down pattern of 0/60/120º, 100% pore interconnectivity, 380-500 µm pore size and 70% porosity, were produced as described previously (Zhou et al. 2007 ).
Biopsy punches were used to produce cylindrical scaffolds of 4 mm height, with an outer diameter of 8 mm and an inner diameter of 4 mm (Fig. 1A-D) . Scaffolds were treated with 1 M NaOH for 6 hrs to hydrolytically cleave mPCL chains and transform ester groups into carboxy and hydroxyl groups for increased hydrophilicity. Then, scaffolds were washed with PBS and 70% ethanol, followed by evaporation and UV sterilisation for 30 min. Further characterisation was performed as reported previously (Reichert et al. 2011 ).
Scaffold fabrication using solution electrospinning (scaffold 2)
Solution electrospun-fabricated mPCL scaffolds were a generous gift from Prof Robert Guldberg (George W Woodruff School of Mechanical Engineering, Georgia Institute of Technology, US). Characterisation was carried out in the Guldberg group as reported previously (Kolambkar et al. 2011) . Briefly, to obtain tubular scaffolds, nanometre-sized sheets were cut into 13×19 mm rectangular shapes, perforated 1.5 mm apart using a 1 mm biopsy punch and wrapped around a steel mandrel to form a tube of 5 mm diameter.
Overlapping edges were aligned with UV glue (Fig. 1E-F ). The fibre diameter was quantified using scanning electron microscopy and a custom MATLAB ® program. Fibre diameter ranged from 51-974 nm, with 82% of the fibres between 50-150 nm. Scaffolds were 300-400 μm thick, with 80-90% porosity and had a pore size of less than 5 μm (Fig. 1G ). Sterilisation was performed as above.
CaP coating of solution electrospun-fabricated scaffolds
Scaffolds were immersed in 70% ethanol for 30 min under vacuum and treated with 37°C pre-warmed 2 M NaOH for 5 min under vacuum, facilitating solution penetration through the entire scaffold to enhance the efficacy of alkaline etching. Then, scaffolds were rinsed with ddH 2 O to neutralise the pH. Simulated Body Fluid (SBF-10x) was prepared and filtered (filter pore size 0.2 µm) as reported previously (Yang et al. 2008) , with pH 6 to increase the solution stability and delay CaP precipitation. A 5 min vacuum treatment was performed to enable SBF infiltration into the scaffolds, followed by 2.5 hrs SBF incubation at 37°C, with SBF changes every 30 min. A 0.5 M NaOH post-treatment for 30 min at 37°C obtained a homogenous CaP coating. Then, scaffolds were rinsed with ddH 2 O, air-dried and placed into a desiccator until usage. To evaluate the distribution of the CaP coating, micro-computed tomography (μ-CT) analysis, with a 12 μm voxel size, at 45 kV and 177 μA was performed.
Following parameters were applied: a threshold of 100 Hounsfield Units, a filter width of 0.8 and filter support of 1.0. Three-dimensional reconstructions were obtained using the software package supplied by Scanco Medical AG (Vaquette et al. 2013 ).
Cell seeding of scaffolds
Sterile mPCL-TCP and mPCL-CaP scaffolds were placed into a 24-well plate, and 1.5×10 5 hOBs in 50 µl medium were equally distributed onto the scaffolds and incubated at 37ºC/5%
CO 2 to allow cell adhesion. After 2 h, 1 ml of medium was carefully added. Cells were cultured in osteogenic medium, containing L-ascorbic acid 2-phosphate (50 μg/ml), β-glycerophosphate (10 mM) and dexamethasone (0.1 μM) over 4 weeks with medium changes twice per week.
Live/dead assay
After 4 weeks of 3D culture, a live/dead assay was performed using fluorescein diacetate (FDA) and propidium iodide (PI) staining. Samples were rinsed with 37°C pre-warmed phenol red-free medium and incubated with FDA (2 µg/ml) and PI (20 µg/ml) staining solution prepared in medium at 37ºC/5% CO 2 for 15 min. Then, samples were washed in PBS, containing CaCl 2 (0.901 mM) and MgCl 2 ×6H 2 O (0.493 mM), and imaged using a Leica SP5 laser scanning confocal microscope.
Assessment of cell morphology
After 4 weeks of 3D culture, samples were fixed with 4% PFA/PBS for 20 min and permeabilised with 0.2% Triton X-100/PBS for 5 min at room temperature. Then, samples were washed in PBS and blocked in 2% BSA/PBS for 20 min, followed by incubation with This article is protected by copyright. All rights reserved.
PicoGreen™ (1:1,000) and rhodamine415-conjugated phalloidin (0.3 U/ml) staining solution in 2% BSA/PBS for 1 h. DAPI (2.5 µg/ml) staining was used to visualise cell nuclei. Samples were washed in PBS to remove any residual staining solution and immersed in PBS and imaged using a Leica SP5 laser scanning confocal microscope.
Implantation of the TEBCs
Animal experiments were conducted as approved by the Queensland University of Technology animal ethics committee (approval number 0900000915). Pre-seeded scaffolds were transplanted into the left and right flank by preparing subcutaneous pockets at the dorsal site of anaesthetised (25 mg/ml xylazine, 50 mg/ml ketamin, 9-10 µl/g body weight i.p.) 7-week old female NOD/SCID mice (ARC, Australia; 3 mice/group). To administer rhBMP-7 (10 µg/scaffold; Olympus Biotech, US) and additional hOBs (8×10 5 /scaffold), 110
μl of fibrin sealant (Tisseel; Baxter, US) was applied to the inner duct of the scaffold intraoperatively ( Fig. 2) . Twelve weeks post-implantation, scaffolds were explanted for subsequent analyses.
Implantation of human non-malignant and malignant breast cell-loaded hydrogels
Polyethylene glycol (PEG)-based hydrogels were prepared as described previously (Loessner et al. 2010) and implanted under general anaesthesia adjacent to the TEBCs.
Briefly, a 5% PEG-Gln/PEG-MMP-Lys precursor stock solution was diluted to the desired PEG concentration in Tris-buffered saline (50 mM, pH 7.6) containing RGD peptide (50 μM)
and CaCl 2 (50 mM). Immediately after adding thrombin-activated factor XIII (10.7 U/ml), the breast cancer cell suspension was added (3.5×10 5 cells/ml). Cell-loaded hydrogel discs were formed by sandwiching 25 μl of the reaction mixture between two sterile glass slides, separated by 1.5 mm spacers and pre-coated with Sigmacote ® , for 30 min at 37ºC/5% CO 2 to allow polymerisation. Then, hydrogels were transferred into 24-well plates and cultured for 3 days prior to implantation. Additionally, triplicate samples per cell line were cultured for 14 days to assess cell upon 3D culture. Four weeks post-implantation of cell-loaded hydrogels, animals were euthanised, scaffolds retrieved and fixed in 4% PFA for 24 hrs followed by 2%
PFA for 48 hrs and stored in 70% ethanol for subsequent analysis. Tumour tissues were explanted and the tumour dimensions measured with a vernier calliper.
Micro-CT analysis
Samples were scanned with a 16 µm voxel size at 55 kV and 145 μA. Following parameters were applied: a threshold of 140 Hounsfield Units, a filter width of 1.0 and filter support of 2.0. X-ray attenuation was correlated to sample density using a standard curve generated by This article is protected by copyright. All rights reserved.
scanning hydroxyapatite phantoms with known mineral density. Three-dimensional reconstructions were obtained using the software package supplied by Scanco Medical AG (Vaquette et al. 2013) , and the bone volume (BV) and total volume (TV) fractions were quantified.
Immunohistochemistry
Samples were treated with 10% EDTA for at least 10 days to assure sufficient decalcification prior to paraffin embedding and serial sectioning (5 µm) using standard procedures.
Samples were stained with Mayer's haematoxylin and eosin (H&E), human-specific antibodies (Table 1) 
Statistical analysis
Datasets were tested for normality using SPSS software (IBM). Normally distributed data were then tested for statistical differences using a Student t-test or one-way ANOVA. P<0.05
was considered significant.
Results
Similar morphology and viability of hOBs grown on different scaffolds
Morphology and viability of hOBs was assessed after 4 weeks of 3D culture on both mPCL-TCP and mPCL-CaP scaffolds by bright-field (Suppl. Fig. 1A , D) and confocal microscopy (Suppl. Fig. 1B -C, E-F), revealing an elongated and spindle-shaped morphology of hOBs forming a dense, interconnected 3D network around the pores of both constructs. Cell viability was greater than 90% (Suppl. Fig. 1C, F) . 2F ) into the murine soft tissues due to its mechanical properties. Both TEBCs were wellvascularised at the time of explantation (Suppl. Fig. 2E, F) . Micro-CT analysis showed that the mineralised tissue was distributed equally throughout both scaffolds and that the mPCL-TCP scaffold had a higher amount of mineralised tissue close to the muscle, but less mineralised tissue close to the skin (Fig. 3A, E) . H&E staining revealed new bone (NB) formation and connective tissue (CT) in both scaffolds (Fig. 3B-C , F-G). TRAP staining indicated the presence of osteoclasts actively degrading the bone-like matrix in both scaffolds, with the mPCL-CaP scaffold group showing a higher amount of TRAP-positive cells (Fig. 3D, H ). Although both scaffolds had equal osteoinductive properties, the mPCLCaP scaffold (scaffold 2) was used for all subsequent experiments due to its better integrative and bone resorption features.
Distincitve cell morphologies of non-malignant and breast cancer cells grown within hydrogels
To assess the morphological differences of the all cell lines tested upon 3D cultures, cells were grown for 14 days within PEG-based hydrogels. Each cell line showed a distinct morphology within the hydrogels as visualised by immunofluorescent staining and confocal This article is protected by copyright. All rights reserved.
laser scanning microscopy. Non-malignant MCF10A cells formed regular-shaped spheroids and a cell layer on top of the hydrogel (Suppl. Fig. 3A ). SUM1315 cells formed only a few multicellular spheroids and remained mainly as single cells (Suppl. Fig. 3B ). No spheroid formation was observed for the MDA-MB-231 cells which were evenly distributed as single cells throughout the hydrogel (Suppl. Fig. 3C ). In contrast, MDA-MB-231BO cells formed grape-like loose cell clusters of difference sizes upon 3D culture (Suppl. Fig. 3D ).
Implantation of invasive breast cancer cells using a hydrogel carrier system led to tumour growth in vivo
Cell-loaded hydrogels were implanted into the flanks of female NOD/SCID mice in a second surgical procedure after 8 weeks post-implantation of the pre-seeded mPCL-CaP scaffolds (Suppl. Fig. 3E-F) . Scaffolds and the cell-loaded hydrogels were fully integrated into the murine soft tissue and were well-vascularised (Suppl. Fig. 3G-H This article is protected by copyright. All rights reserved.
areas were also detected in the MDA-MB-231 (Fig. 5I ) and MDA-MB-231BO (Fig. 5M) tumours. H&E staining revealed residual PCL in all groups and indicated different tissue types, including new bone (NB), bone marrow (BM), fibrous connective tissue (CT) and tumour tissue (T), with clear blood vessel formation (Fig. 5B-C , F-G, J-K, N-O). New bone formation was detected in the scaffold area and in the hollow parts of the scaffold, where hOBs in addition to rhBMP-7 had been administered. TRAP staining (Fig. 5D , H, L, P; 
Discussion
The development of breast cancer-related bone metastases is a highly dynamic and complex process, which can be mimicked in an in vivo disease model consisting of the two main components -a humanised breast tumour and a humanised organ bone. To achieve sufficient bone formation through TE strategies, the first-generation FDA-approved mPCL scaffold was combined with bone marrow-derived stromal cells that had to be immobilised onto the scaffold using fibrin sealant because of its poor protein and cell adhesive properties.
To circumvent this approach, a second-generation composite scaffold made from mPCL and TCP was established by fused deposition modelling (Zhou et al. 2007 ). The advantages of composite scaffolds are their improved biomechanical and degradation properties, increased strength via the ceramic phase, toughness and plasticity via the polymer phase (Hutmacher and Cool 2007) . These improvements have resulted in advanced cell seeding, adhesion, control and/or incorporation of biological factors like BMPs (Rai et al. 2005) . In this study, a high seeding efficiency 8 hrs after administration of hOBs onto the mPCL-TCP scaffold was achieved (data not shown).
Porcine bone marrow-derived stromal cells in conjunction with mPCL-TCP scaffolds were used in a subcutaneous rat model, showing sufficient bone formation (Zhou et al. 2007 ).
Bone regenerative applications using mPCL-TCP scaffolds, which was loaded with collagentype I and rhBMP-2, demonstrated a full closure of a critical-sized rat calvarial defect 15 weeks post-implantation (Sawyer et al. 2009 ). Neither short-term nor long-term foreign body This article is protected by copyright. All rights reserved.
reactions were detectable underscoring the high immunocompatibility of mPCL (Sawyer et al. 2009 ). In this study, osteogenic progenitor cells and rhBMP-7 were used to further increase the osteoinductivity and biological activity of the mPCL-TCP scaffolds, but with mixed results (scaffold 1). The major differences between this study and the aforementioned studies were the subcutaneous localisation of the scaffold and the cell type used. Our group has already shown that ovine osteoblasts grown on mPCL-TCP scaffolds and addition of rhBMP-7 resulted in a sufficient amount of bone (Reichert et al. 2011) , but yet was not able to achieve similar results in the present study using human osteogenic progenitor cells. One reason might be the mechanical properties of the scaffold as they are favourable for bone TE in orthotopic defect models but can present pitfalls in humanised subcutaneous NOD/SCID mice models.
Hence, it was sought to find a suitable scaffold to engineer a humanised bone microenvironment and upon this to develop an in vivo disease model to investigate cancerrelated metastasis to this human bone equivalent. Therefore, a bone TE approach for the in vitro culture of hOBs was combined with the in vitro 3D culture of non-malignant and malignant breast cells within PEG-based hydrogels. Upon implantation of the TEBCs (scaffold 2), a complex organ bone composed of human and murine elements was formed.
In addition, the implantation of cell-loaded hydrogels acted as delivery system of human nonmalignant and malignant breast cells in NOD/SCID mice.
The mechanical properties are critical for the treatment of bone defects, where an intrinsic stability of the scaffold is desired, but were causing complication in the ectopic side in the NOD/SCID model. The delicate skin of NOD/SCID mice was not strong enough to aid the integration of the scaffold into the soft tissue of the murine flanks to the same extent as reported for the ectopic bone formation in a rat model (Zhou et al. 2007 ). This incomplete integration might be responsible for the apparent gradient in bone formation from the skin towards the muscle. Thus, a mPCL-CaP scaffold (scaffold 2) was chosen for the breast cancer-related metastasis experiments (Kolambkar et al. 2010 ) (Kolambkar et al. 2011) . The major differences between both scaffolds are the fabrication technique, fused deposition modelling versus solution electrospinning, and the scaffold design, cylindrical versus tubular.
In line with a previous study (Kolambkar et al. 2010) , hOBs formed a dense cell sheet when grown on the perforated mPCL-CaP scaffold and remained viable over 4 weeks in vitro.
Bone TE properties of these scaffolds were successfully established in a rat femoral defect model, in which scaffolds were combined with rhBMP-2 via an alginate hydrogel, leading to new bone formation and bridging the defect within 12 weeks post-implantation (Kolambkar et al. 2011) . In the presented study, the orthotopic approach (Kolambkar et al. 2011) was This article is protected by copyright. All rights reserved.
translated to an ectopic setting by improving its bioactivity. The addition of CaP coating, hOBs, which have been osteogenically stimulated pre-implantation, and rhBMP-7 resulted in a humanised organ bone at an ectopic site in NOD/SCID mice, allowing the study of cancerrelated bone metastasis.
Only few groups use a bone TE approach to study the mechanisms of bone metastasis in ectopic NOD/SCID models. Moreau et al. (Moreau et al. 2007 ) utilised a biodegradable silk scaffold together with human mesenchymal stem cells (hMSCs) and rhBMP-2. Development of matured bone occurred 7 weeks after in vitro culture under osteogenic conditions, but did not mediate breast cancer cell colonisation (Moreau et al. 2007) . Instead, the more primitive bone microenvironment resulted in a higher amount of breast cancer cell colonisation 3 months post-implantation at its orthotopic site, the mammary fat pad. The application of this silk scaffold combined with either hMSC or rhBMP-2 had the highest effect on metastatic spread compared to their combination (Moreau et al. 2007 ). This suggests breast cancer cells homed towards hMSCs grown on the silk scaffold rather than towards the tissueengineered bone construct (Moreau et al. 2007 ). The presented TE approach herein utilised hOBs in addition to rhBMP-7 in fibrin sealant and aimed for the generation of mature human bone as target tissue for breast cancer cell colonisation. Thus, it is of utmost importance to represent all elements of the organ bone in an ectopic bone assay that includes mineralised tissue, osteoblasts, osteocytes, osteoclasts and bone marrow. Several other studies have shown that TE approaches lead to mineralised tissue formation in ectopic bone models, but without the development of bone marrow (Kuperwasser et al. 2005 ) (Moreau et al. 2007 ) (Roldan et al. 2010 ).
Our bone TE approach indicated that the newly formed bone is of human origin.
Immunohistochemical analysis indicated the presence of matrix-embedded osteocytes of human origin as well as human-derived osteocalcin and collagen type-I in the TEBCs. The appearance of human spindle-shaped cells in the connective and cartilaginous tissues suggests that the implanted hOBs and not the murine cells mainly participated in the endochondral bone formation. The human-derived bone-specific matrix proteins osteocalcin and collagen type-I were mostly located in the center of the organ bone, demonstrating that the outer cortical-like shell surrounding the scaffold is a chimera of both human and murine extracellular matrix. This finding is consistent with our previous approach (Thibaudeau et al. 2014a ) (Thibaudeau et al. 2014b) . To date, several groups ulilised approaches, such as Matrigel or fibrin gels, other than tissue-engineered bone constructs to humanise the bone marrow microenvironment to study for example normal and malignant hematopoiesis (Sacchetti et al. 2007 ) (Chen et al. 2012 ) (Reinisch et al. 2016) . 3D bioprinting can be used to generate a biomimetic bone matrix that consists of gelatine-based hydrogels loaded with This article is protected by copyright. All rights reserved.
human osteoblasts or human bone marrow-derived MSCs to study their functional interaction with breast cancer cells (Zhou et al. 2016) .
A well-established hydrogel model was used to deliver human breast cancer cells. Evidently, 3D cell culture platforms mimic physiological cellular microenvironment, mimicking the natural cellular behaviour compared to 2D cultures on tissue culture plastic. Our group established PEG-based hydrogels as 3D platform for human ovarian cancer cells (Loessner et al. 2010) . These synthetically-derived biomaterials are well-defined opposed to other commonly-used biomaterials in the cancer research, like Matrigel, which harbour high batchto-batch variations that complicate data analysis (Loessner et al. 2010) . To examine the integral step of the metastatic cascade, the bone colonisation by breast cancer cells, PEGbased hydrogels were used to implant breast cancer cells adjacent to the TEBCs. Tumour formation was observed within 4 weeks post-implantation. Macroscopic analysis upon explantation showed sufficient vascularisation of the tumours and the TEBCs as well as blood vessels shared by both. A significantly higher number of osteoclasts were found in the TEBCs in conjunction with the invasive breast cancer cells compared to the control. These findings indicate reciprocal interactions between the tumour and TEBCs. However, future experiments need to be performed to further confirm these interactions.
The majority of ectopic bone models utilise human bone chips (Kuperwasser et al. 2005) or silk scaffolds seeded with hMSCs (Moreau et al. 2007 ) that are implanted into immunesuppressed animals. While the implanted human bone chips are often poorly vascularised and have a high dehiscence rate, in turn, previous bone TE approaches often failed to produce sufficient bone volume to allow the analysis of reciprocal interactions with breast cancer cells. In this study, a notably large bone volume in NOD/SCID mice was engineered.
Strikingly, this bone comprises hallmarks of the organ bone, such as bone marrow, reticular and adipocytic stroma, hematopoietic cells, bone-lining osteoblasts and osteoclasts. This in vivo disease model significantly increased osteoclast recruitment, thus recapitulating clinically relevant osteolytic lesions. It should be noted that this humanised model using a subcutaneous approach in NOD/SCID mice still harbours features of both species, human and murine. As NOD/SCID mice are hosting the human TEBCs, it is assumed that the vascularisation, osteoclasts and the bone marrow are provided by the murine host. Our group has shown that osteoblasts remained at the implantations site within the mineralized matrix when using ovine osteoblasts instead of hOBs in conjunction with rhBMP-7 and the identical mPCL-TCP scaffold (Reichert et al. 2011) . Hence, it is assumed that hOBs also This article is protected by copyright. All rights reserved.
remain within their bone-like matrix deposited onto the scaffold, thus providing a humanised organ bone within the murine host.
